Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 2006

View Archived Issues

Ostabolin-C safe, active in healthy, older volunteers

Oral gallium superior to intravenous formulation in vitro

Mechanism of PT-100 antitumor activity explored

Antitoxicity, inhibitory effects of As4O6 investigated in vitro

Neuropeptide Y Y1 receptor a potential target for breast cancer treatment

Evaluation of Coenzyme Q10 in Duchenne muscular dystrophy moves to phase III

Positive interim phase II results for CUV-1647 in polymorphous light eruption

Chemokine Therapeutics reacquires CTCE-0214 rights

YM BioSciences to acquire Eximias Pharmaceutical

Athenagen acquires Osprey Pharmaceutical

GSK obtains rights to Japan Tobacco drug in MEK inhibition

Pfizer to acquire rights to fesoterodine for overactive bladder

FermaVir receives FDA advice on development of shingles drug CF-1743

Cortex receives written confirmation on CX-717 clinical hold

Fast track designation for TheraQuest's Tramadol ER

New phase III trial studies Velcade with rituximab in follicular lymphoma

Eprodisate NDA filed and granted priority review for AA amyloidosis

American Pharmaceutical Partners and American BioScience merge

New gamma-secretase inhibitor markedly reduces Abeta levels in vivo

Novel agents for urological disorders disclosed in recent patent literature

Recent patents impart new agents for obesity and lipoprotein disorders

Fast track status for thrombin receptor antagonist SCH-530348

FDA accepts Novartis' Rasilez submission for review

Roche submits BLA for CERA

New anticoagulant agents emerge from sanofi-aventis R&D

Oncolytic adenoviruses plus cytostatic agents as novel approach for prostate cancer

New potent, highly selective Tie-2 kinase inhibitor from Amgen demonstrates in vivo efficacy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...